A clincial study comparing the effectiveness of two drugs, named Ritux
RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis – RIFUND-MS
What was tested
Treatment tested
- Rituximab
B-lymphocyte antigen CD20 binding agent
Compared with
- Dimethyl fumarate
Kelch-like ECH-associated protein 1 inhibitor
What it measured
Main measures
The primary endpoints of this study is
Other measures (1)
The secondary endpoints are
Papers
Loading reviews and guidelines…
Related trials
- A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory
Phase 1 · Not yet recruiting
Still running
- Study of an On-Body Injection System for Home Use of Ocrelizumab in Pe
Phase 3 · Running, not recruiting
Still running
- A Study of C-CAR168 in the Treatment of Central Nervous System Autoimm
Phase 1 · Not yet recruiting
Still running
- Immune System Effects in Children Born to Women With Multiple Sclerosi
Not yet recruiting
Still running
- Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue
Not a drug-phase study · Not yet recruiting
Still running
- B-cell Depletion in Offspring to Women With MS Under Immunomodulatory
Status unknown
No results found
History
- In scope changed from true to false
Started
Oct 2015
Assembled by software from public sources.